Ann: Security Class Reinstatement to Quotation- OPTOB, page-428

Just adding to the above, it may actually perform better (more letters) at the longer timeframe, 52 vs 24.

In a real-world study, patients treated with intravitreal aflibercept (a similar anti-VEGF drug) showed: Mean vision gain of 17.8 letters at week 24 • Mean vision gain of 15.1 letters at week 52.

Source - https://pmc.ncbi.nlm.nih.gov/articles/PMC6514015/?t

So my thinking is that if there is a decline in letters the longer the treatment with monotherapy and some of that vision loss is attributed to the upregulation of VGF C&D or any other mechanism in which Sozinibercept mitigates, then we can extrapolate that there would be wider gap (more letters) the longer the timeframe of treatment. The gap could be quite large even out to 5 years.

Cheers